NCT04228211: UPC

Utrecht Prostate Cohort for Cancer Treatment Intervention Studies and Long-term Evaluation

Recruiting now Last updated 5 March 2026

What this trial tests

trial in Prostate Cancer in 1,500 participants. Currently enrolling.

Timeline

5 February 2020

Primary endpoint
5 February 2030

5 February 2033

Quick facts

Lead sponsor	UMC Utrecht
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,500
Start date	5 February 2020
Primary completion	5 February 2030
Estimated completion	5 February 2033
Sites	2 locations across Netherlands

Conditions studied

• Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

UMC Utrecht — full company profile →

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rationale: Prostate cancer is the most common cancer in men worldwide. Survival rates are high due to the typically non-aggressive nature of disease and effective treatments. Radical treatments such as surgery and radiotherapy often cause toxicity and long term side effects. Based on current available literature, the choice for primary therapy for clinically localised prostate cancer has a negative impact on cancer-specific quality of life (QOL). New interventional treatments are being developed. The investigators aim to build a multidisciplinary prostate cancer cohort which will serve as a multi-trial facility for interventional treatment studies. The Trials within Cohorts (TwiCs) design, also known as cohort multiple Randomized Controlled Trial design (cmRCT) will be conducted and as a prospective registry for assessment of long-term safety, performance and effectiveness new treatment interventions.

Objective: To set up a cohort that will serve as a multi-trial platform and facilitate evaluation of new interventional treatment for prostate cancer.

Study design: Observational, prospective cohort study, according to the 'Trials within Cohorts' (TwiCs) design.

Study population: All patients with newly diagnosed histologically proven prostate cancer.

Main study parameters/endpoints: Clinical parameters (e.g. co-morbidity, oncological history, symptoms, imaging, technical and treatment data), clinical endpoints (e.g. toxicity, and survival outcomes) and patient reported outcomes (e.g. QOL).

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Deep learning for automated contouring of neurovascular structures on magnetic resonance imaging for prostate cancer patients.
   van den Berg I, Savenije MHF, Teunissen FR, van de Pol SMG, et al · · 2023 · cited 11× · PMID 37312973 · DOI 10.1016/j.phro.2023.100453
2. The first patient-reported outcomes from the Utrecht Prostate Cohort (UPC): the first platform facilitating 'trials within cohorts' (TwiCs) for the evaluation of interventions for prostate cancer.
   Teunissen FR, Willigenburg T, Meijer RP, van Melick HHE, et al · · 2022 · cited 11× · PMID 35861861 · DOI 10.1007/s00345-022-04092-2
3. An Overview of Patient-reported Outcomes for Men with Prostate Cancer: Results from the PIONEER Consortium.
   Remmers S, Beyer K, Lalmahomed TA, Prinsen P, et al · · 2025 · cited 2× · PMID 39801658 · DOI 10.1016/j.euros.2024.11.009
4. Patient preferences for treatment modalities for localised prostate cancer.
   Teunissen FR, Hehakaya C, Meijer RP, van Melick HHE, et al · · 2023 · cited 2× · PMID 36816141 · DOI 10.1002/bco2.198
5. Added value of non-rigid image registration for intrafraction dose accumulation in magnetic resonance imaging-guided prostate radiotherapy.
   Tsekas G, Zachiu C, Bol GH, de Boer JCJ, et al · · 2025 · cited 1× · PMID 40026907 · DOI 10.1016/j.phro.2025.100711
6. Automated pelvic MRI measurements associated with urinary incontinence for prostate cancer patients undergoing radical prostatectomy.
   van den Berg I, Spaans RN, Wessels FJ, van der Hoeven EJRJ, et al · · 2024 · cited 1× · PMID 38165522 · DOI 10.1186/s41747-023-00402-4